Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure

  • Technology appraisal guidance
  • TA626
  • Published: 
Download guidance (PDF)

Update information

Minor changes since publication

August 2020: Section 4.1 updated. The period the NHS in England has to comply with the recommendations is extended to within 3 months of the commercial launch of avatrombopag in England.

ISBN: 978-1-4731-3744-8